Dear Colleagues,
You are kindly asked to participate to a Survey entitled: “Unprovoked venous thromboembolism in subjects with an established atherosclerotic cardiovascular disease: what is the best antithrombotic strategy after 6 months from venous thromboembolic event? The case of peripheral artery disease”.
At present, the best antithrombotic treatment for patients who have an established atherosclerotic cardiovascular disease (ASCVD) and require secondary prevention of venous thromboembolism (VTE) in unknown. An interesting example is subjects with peripheral artery disease (PAD) who suffered from unprovoked VTE, in whom extended (beyond 6 months from the VTE index event) antithrombotic therapy should have three distinct goals: 1) to prevent VTE recurrence, 2) to reduce major adverse cardiovascular events (MACE), and 3) to reduce major adverse limb events (MALE). In addition, the achievement of these goals must be balanced by a tolerable haemorrhagic risk profile of the chosen antithrombotic strategy.
We are interested in determining how expert physicians like you manage antithrombotic therapy in these subjects. For this reason, we have prepared a survey that presents four different clinical scenarios and proposes six possible therapeutic options for each case. It will take approximately fifteen minutes to complete the survey and we hope that you will be willing to participate. All the answers will be kept anonymous, all data will be analyzed in aggregate form and cannot be traced back to individual participants. Should you have any questions regarding this survey, please contact Prof. Roberto Pola (roberto.pola@unicatt.it).
Thank you for participating!
You are kindly asked to participate to a Survey entitled: “Unprovoked venous thromboembolism in subjects with an established atherosclerotic cardiovascular disease: what is the best antithrombotic strategy after 6 months from venous thromboembolic event? The case of peripheral artery disease”.
At present, the best antithrombotic treatment for patients who have an established atherosclerotic cardiovascular disease (ASCVD) and require secondary prevention of venous thromboembolism (VTE) in unknown. An interesting example is subjects with peripheral artery disease (PAD) who suffered from unprovoked VTE, in whom extended (beyond 6 months from the VTE index event) antithrombotic therapy should have three distinct goals: 1) to prevent VTE recurrence, 2) to reduce major adverse cardiovascular events (MACE), and 3) to reduce major adverse limb events (MALE). In addition, the achievement of these goals must be balanced by a tolerable haemorrhagic risk profile of the chosen antithrombotic strategy.
We are interested in determining how expert physicians like you manage antithrombotic therapy in these subjects. For this reason, we have prepared a survey that presents four different clinical scenarios and proposes six possible therapeutic options for each case. It will take approximately fifteen minutes to complete the survey and we hope that you will be willing to participate. All the answers will be kept anonymous, all data will be analyzed in aggregate form and cannot be traced back to individual participants. Should you have any questions regarding this survey, please contact Prof. Roberto Pola (roberto.pola@unicatt.it).
Thank you for participating!